Dr. Steven Abman is the Director of the Pediatric Heart Lung Center (PHLC), and coordinates several clinical and laboratory based research projects on mechanisms that contribute to the development of BPD and pulmonary hypertension in newborns and older children. He is also the founder and Director of the Pediatric Pulmonary Hypertension Network, which is a multicenter program to develop novel insights into the natural history and treatment of childhood pulmonary hypertension involving centers throughout North America.
Dr. Christopher Baker’s research focuses on the role of endothelial progenitor cells (EPCs) from human umbilical cord samples in the pathobiology of BPD and mechanisms underlying their function during development.
Dr. Jason Gien is currently studying the role of endothelial cells during lung vascular development and the effects of intrauterine stress on altering endothelial function in disease models.
Dr. Dunbar Ivy leads numerous studies on the clinical course and effects of diverse therapies in children with pulmonary hypertension.
Dr. John Kinsella’s research includes clinical studies on the role of inhaled NO and nasal CPAP in prevention of BPD in human preterm infants, as well as clinical studies of sildenafil therapy in term infants with pulmonary hypertension.
Dr. Peter Mourani’s research examines mechanisms that contribute to the development of BPD in human preterm infants. He is currently investigating genetic factors that may increase susceptibility for BPD and pulmonary hypertension. He is also investigating the epidemiology of BPD and the role of early microbial colonization of the preterm infant with the risk for BPD.
Dr. Jen Ruey Tang studies prenatal mechanisms that impair lung development and contribute to high risk for BPD in rodent and cell culture studies.